Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.86 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.86 |
| ▸ | SRC | P12931 | 2/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.86 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.86 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.86 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.86 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.86 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.86 |
| ▸ | LDHA | P00338 | 1/20 | 0.86 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.86 |
| ▸ | FBP1 | P09467 | 1/20 | 0.86 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.86 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.86 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.86 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.86 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine Phosphate SCHEMBL2512522 | 0.93 | P2RY1 (0.96) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL11977309 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL19420134 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL20277555 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL144997 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL13170051 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL132458 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| SCHEMBL5055892 | 0.93 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL8572634 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| Adenosine Phosphate SCHEMBL1338615 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427425-A4 | METHOD OF TREATMENT OF OBESITY AND PARALYZED MUSCLE AND ERGOGENIC AIDS | UNIV BRIGHAM YOUNG (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1427425-A1 | METHOD OF TREATMENT OF OBESITY AND PARALYZED MUSCLE AND ERGOGENIC AIDS | Brigham Young University (US) | 2004-06-16 | — | — | EP | claimed |
| US-20030212034-A1 | Method of treatment of obesity and paralyzed muscle and ergogenic aids | WINDER WILLIAM W (US) | 2003-11-13 | — | — | US | claimed |
| US-20030212013-A1 | Use of amp kinase activators for treatment type 2 diabetes and insulin resistance | BRIGHAM YOUNG UNIVERSITY | 2003-11-13 | — | — | US | claimed |
| WO-2001097816-A1 | USE OF AMP KINASE ACTIVATORS FOR TREATMENT OF TYPE 2 DIABETES AND INSULIN RESISTANCE | BRIGHAM YOUNG UNIVERSITY (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001093874-A1 | METHOD OF TREATMENT OF OBESITY AND PARALYZED MUSCLE AND ERGOGENIC AIDS | BRIGHAM YOUNG UNIVERSITY (US) | 2001-12-13 | — | — | WO | claimed |
| US-20250076302-A1 | DETECTING THE PRESENCE OF URINARY STONE DISEASE USING A PLURALITY OF URINARY METABOLITES | THE CLEVELAND CLINIC FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20250057860-A1 | READY-TO-DILUTE FORMULATION | EMPHASCIENCE, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023076878-A1 | READY-TO-DILUTE FORMULATION | EMPHASCIENCE INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| WO-1996029345-A1 | NOVEL INOTROPIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-09-26 | — | — | WO | disclosed |
| WO-1996020946-A1 | FLAVIN ADENINE DINUCLEOTIDE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, AND THEIR ACTIVITY AS MONOAMINE OXIDASE INHIBITORS | RESEARCH DEVELOPMENT FOUNDATION (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1989009283-A1 | PYROPHOSPHATE-BASED METHOD AND APPARATUS FOR SEQUENCING NUCLEIC ACIDS | HYMAN EDWARD DAVID (US) | 1989-10-05 | — | — | WO | disclosed |
| EP-0090405-B1 | NOVEL AZOLE DINUCLEOTIDE COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BRIGHAM YOUNG UNIVERSITY (US) | 1986-06-25 | — | — | EP | disclosed |
| US-4594415-A | Viricides | ROBINS ROLAND K (US) | 1986-06-10 | — | — | US | disclosed |
| US-4544741-A | Azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY, PROVO, UT., A NONPROFIT CORP. OF UT | 1985-10-01 | — | — | US | disclosed |
| EP-0090405-A1 | Novel azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY (US) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057860-A1 | READY-TO-DILUTE FORMULATION | PRPF6, PNP, PRNP | P2RY1 299/4885P2RY2 835/4885SRC 4806/4885 |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.